BRD2 and ovarian carcinoma: The deca peptide (BI-10) derived from FSH-BI and conjugated with near-infrared fluorescence dye was investigated and shown to bind to ovarian cancer cells in vivo with low binding affinity and repeatable differential binding to ovarian tumors in mice.